文献速递类风湿关节炎

Medicare中类风湿关节炎常用传统与生物改善病情抗风湿药支出趋势

Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis.
PubMed 文献 · Semin Arthritis Rheum · 2020-08-28

该研究基于2012–2017年Medicare药品支出数据,分析传统改善病情抗风湿药(cDMARDs)与生物改善病情抗风湿药(bDMARDs)的总支出与单位成本趋势。支出增长主要由单位成本上升驱动而非受益人数增加。

要点

  • 支出增长主要源于单位成本上升,而非受益人数增加。
  • 羟氯喹仿制药单位成本增6倍,阿达木单抗和依那西普增2倍。

核心结论

  • 尽管多种cDMARDs仿制药已上市数十年,其单位成本仍大幅上升以「跟上」bDMARDs的涨幅。
  • 随着老年类风湿关节炎患者增多,可能需要政策干预以降低生物制剂和传统DMARDs的支出。

研究设计与样本

  • 基于2012–2017年Medicare药品支出数据的回顾性分析,覆盖所有B部分(按服务收费)和D部分药品。
  • 总支出按各药品制剂支出加总计算,单位药品成本按总支出除以配发剂量数计算。

主要发现

  • 支出增长主要由药品单位成本驱动,而非受益人数增加。
  • 仿制药羟氯喹单位成本增6倍,甲氨蝶呤和来氟米特紧随其后。
  • bDMARDs中阿达木单抗和依那西普单位成本增2倍,办公室给药产品增幅较小。

临床怎么用

  • 风湿免疫科医生应关注cDMARDs单位成本持续上涨对患者自付费用和医保支出的影响。
  • 在制定治疗方案时,需综合考虑bDMARDs与cDMARDs的成本趋势及患者经济负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biologic disease modifying agents (bDMARDs) are an integral part of rheumatoid arthritis treatment guidelines but are associated with significant cost in the US. We present the trends in total spending and unit cost of conventional DMARDs (cDMARDs) as compared to bDMARDs in Medicare program. METHODS: We used the Medicare drug spending data for the year 2012-2017 covering all part B (fee-for-service) and part D drugs. Total spending was calculated by summing spending across various drug formulations and unit drug cost by dividing total spending by number of doses dispensed. We present the 6-year trends in total spending, total beneficiary count and unit costs of each of the commonly used cDMARDs and bDMARDs. RESULTS: Between 2012 and 2017, the total spending on the cDMARDs increased 5-folds from $98 million to $579 million; this was fraction of total spending on bDMARDs which increased from $4.3 to $10.0 billion. This increase was driven largely by unit costs of drug rather than number of beneficiaries. There was a 6-fold increase in the unit cost of generic hydroxychloroquine followed by methotrexate and leflunomide. Amongst bDMARDs, adalimumab and etanercept unit cost increased by 2-folds. The increase was less pronounced for office-administered products. CONCLUSIONS: Despite the availability of several generic cDMARDs over decades, there were steep increases in the unit cost of these agents to "keep pace" with the increases in bDMARDs. As the number of elderly rheumatoid arthritis patients increases, policy interventions might be required to reduce the spending on both biologics and conventional DMARDs.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Dalal DS, Zhang T, Shireman TI, et al. Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis. Semin Arthritis Rheum. 2020. PMID: 32896694. doi:10.1016/j.semarthrit.2020.08.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。